Published in Pharma Law Weekly, November 22nd, 2005
The results are from study extensions initially involving 518 and 161 patients treated with Fosrenol for periods of up to 1 and 3 years, respectively. Prior to the extensions, those patients taking Fosrenol were continued on the treatment, and those receiving calcium carbonate were switched to Fosrenol.
At the end of the first, 6-month study extension, the mean...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Pharma Law Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.